is a Phase 3 clinical trial of an investigational antisense drug called eplontersen, formerly known as AKCEA-TTR-LRx, for people living with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN).
Strictly Necessary Cookies
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.